Efficacy and Safety of Rofecoxib in Patients with Chronic Low Back Pain: Results from Two 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trials
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
STUDY DESIGN: Two replicate, 4-week, randomized, double-blind, placebo-controlled, trials of rofecoxib 25 and 50 mg versus placebo for chronic low back pain. OBJECTIVES: To determine the efficacy and safety of two doses of rofecoxib compared to placebo in the treatment of chronic low back pain. SUMMARY OF BACKGROUND DATA: Although nonsteroidal anti-inflammatory drugs are commonly prescribed for chronic low back pain, their efficacy is unproven and toxicity can be serious. These studies evaluated the efficacy and tolerability of rofecoxib, a selective COX-2 inhibitor, in the treatment of chronic low back pain. METHODS: Patients with chronic low back pain were randomized 1:1:1 to rofecoxib 25 mg, 50 mg, or placebo once daily. Primary endpoint: Low Back Pain Intensity. Secondary endpoints: Pain Bothersomeness, Global Assessments of Response to Therapy, Global Assessment of Disease Status, Roland-Morris Disability Questionnaire, SF-12 Health Survey, Use of Rescue Acetaminophen, and Discontinuations Due to Lack of Efficacy. RESULTS: Combining both studies, 690 patients were randomized to placebo (N = 228), rofecoxib 25 mg (N = 233), or rofecoxib 50 mg (N = 229). Mean (+/- SD) age was 53.4 (+/- 12.9) years, pain duration 12.1 (+/- 11.8) years, 62.3% female. Both rofecoxib groups improved significantly. Mean differences from placebo in pain intensity were -13.50 mm, -13.81 mm (25, 50 mg doses) respectively (P < 0.001). Both regimens were superior to placebo in eight of nine secondary endpoints. Fifty mg provided no advantage over 25 mg. Both rofecoxib regimens were well tolerated, although 25 mg had a slightly better safety profile. CONCLUSIONS: Rofecoxib significantly reduced chronic low back pain in adults and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Study of the Natural History of Back Pain: Part I
ROLAND, M., & MORRIS, R. (1983) · Spine · doi:10.1097/00007632-198303000-00004 · Cited by 3,395
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Outcome Measures for Low Back Pain Research: A Proposal for Standardized Use
Deyo, R. A., Battie, M., Beurskens, A. J. H. M., Bombardier, C., Croft, P., Koes, B., Malmivaara, A., Roland, M., Von Korff, M., & Waddell, G. (1998) · Spine · doi:10.1097/00007632-199809150-00018 · Cited by 1,229
Cited by
Qaseem, A., Wilt, T. J., McLean, R. M., Forciea, M. A., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m16-2367 · Cited by 3,234
Chou, R., Deyo, R., Friedly, J., Skelly, A., Weimer, M., Fu, R., Dana, T., Kraegel, P., Griffin, J., & Grusing, S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2458 · Cited by 864
Ross, J. S., Hill, K. P., Egilman, D. S., & Krumholz, H. M. (2008) · JAMA · doi:10.1001/jama.299.15.1800 · Cited by 450
Non-steroidal anti-inflammatory drugs for chronic low back pain
Enthoven, W. T., Roelofs, P. D., Deyo, R. A., van Tulder, M. W., & Koes, B. W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012087 · Cited by 399
Non-steroidal anti-inflammatory drugs for low back pain
Roelofs, P. D., Deyo, R. A., Koes, B. W., Scholten, R. J., & van Tulder, M. W. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000396.pub3 · Cited by 398
Metadata
- Authors
- Katz, N., Ju, W. D., Krupa, D. A., Sperling, R. S., Bozalis Rodgers, D., Gertz, B. J., Gimbel, J., Coleman, S., Fisher, C., Nabizadeh, S., & Borenstein, D.
- Venue
- Spine
- Published
- 2003-05
- Volume
- 28
- Issue
- 9
- Pages
- 851-858
- ISSN
- 0362-2436 (ISSN-L)
- OpenAlex
- W1985803081
- Cited by
- 60
- References
- 3
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Rofecoxib in Patients with Chronic Low Back Pain: Results from Two 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trials. https://app.cochat.ai/papers/10.1097/01.brs.0000059762.89308.97
- The paper
- Katz, N., Ju, W. D., Krupa, D. A., Sperling, R. S., Bozalis Rodgers, D., Gertz, B. J., Gimbel, J., Coleman, S., Fisher, C., Nabizadeh, S., & Borenstein, D. (2003). Efficacy and Safety of Rofecoxib in Patients with Chronic Low Back Pain: Results from Two 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trials. Spine. https://doi.org/10.1097/01.brs.0000059762.89308.97
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.